Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
At a press conference at ESMO 2014, Dr Machiels presents the results of his study which looked at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer.
Read the news story or watch the interview for more.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
Overview of the management of HER2-low breast cancer patients